Docetaxel
- TRADE NAME: Taxotere (Sanofi-Aventis)
- INDICATIONS: Metastatic breast cancer, non-small cell lung cancer; with prednisone in hormone refractory prostate cancer; with cisplatin and fluorouracil for gastric adenocarcinoma and squamous cell carcinoma of the head and neck cancer
- CLASS: Taxane, Antineoplastic
- HALF-LIFE: 11–18 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aldesleukin, Aprepitant, Cyclosporine, CYP3A4 inhibitors, Erythromycin, Itraconazole, Ketoconazole, Prednisone, Ritonavir, Sorafenib
PREGNANCY CATEGORY: D
TOXIC DEATHS, HEPATOTOXICITY, NEUTROPENIA, HYPERSENSITIVITY REACTIONS, and FLUID RETENTION
See full prescribing information for complete boxed warning.
Contraindicated in patients with hypersensitivity to docetaxel or polysorbate 80, or with neutrophil counts of <1500 cells/mm3.
Please login to see the rest of this drug profile
SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC
OTIC
OCULAR
LOCAL
OTHER
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric